Department of Anesthesiology, University of Michigan, 4172 Cardiovascular Center, 1500 E. Medical Center Drive, Ann Arbor, MI, USA.
The Max Harry Weil Institute for Critical Care Research and Innovation, Ann Arbor, MI, USA.
BMC Anesthesiol. 2022 Sep 10;22(1):288. doi: 10.1186/s12871-022-01817-z.
There are few data to guide the intraoperative management of patients with reduced left ventricular ejection fraction (LVEF). This study aimed to describe how patients with reduced LVEF are managed differently and to identify and treatments had a different risk profile in this population.
We performed a retrospective cohort study of adult patients who underwent general anesthesia for non-cardiac surgery. The effect of anesthesia medications and fluid balance was compared between those with and without a reduced preoperative LVEF. The primary outcome was a composite of acute kidney injury, myocardial injury, pulmonary complications, and 30-day mortality. Multivariable logistic regression was used to adjust for confounders. Treatments that affected patients with reduced LVEF differently were defined as those associated with the primary outcome that also had a significant interaction with LVEF.
A total of 9420 patients were included. Patients with reduced LVEF tended to have a less positive fluid balance. Etomidate, calcium, and phenylephrine were use more frequently, while propofol and remifentanil were used less frequently. Remifentanil affected patients with reduced LVEF differently than those without (interaction term OR 2.71, 95% CI 1.30-5.68, p = 0.008). While the use of remifentanil was associated with fewer complications in patients with normal systolic function (OR 0.54, 95% CI 0.42-0.68, p < 0.001), it was associated with an increase in complications in patients with reduced LVEF (OR = 3.13, 95% CI 3.06-5.98, p = 0.026).
Patients with a reduced preoperative LVEF are treated differently than those with a normal LVEF when undergoing non-cardiac surgery. An association was found between the use of remifentanil and an increase in postoperative adverse events that was unique to this population. Future research is needed to determine if this relationship is secondary to the medication itself or reflects a difference in how remifentanil is used in patients with reduced LVEF.
目前关于左心室射血分数(LVEF)降低的患者,术中管理的相关数据有限。本研究旨在描述不同左心室射血分数降低的患者管理方式的差异,并识别和治疗在该人群中具有不同风险特征的患者。
我们进行了一项回顾性队列研究,纳入了接受非心脏手术全身麻醉的成年患者。比较了术前 LVEF 降低的患者和 LVEF 正常的患者之间麻醉药物和液体平衡的差异。主要结局是急性肾损伤、心肌损伤、肺部并发症和 30 天死亡率的复合结局。多变量逻辑回归用于调整混杂因素。对左心室射血分数降低的患者有不同影响的治疗定义为与主要结局相关且与 LVEF 有显著交互作用的治疗。
共纳入 9420 例患者。与 LVEF 正常的患者相比,LVEF 降低的患者液体平衡往往更呈负性。依托咪酯、钙和苯肾上腺素的使用率更高,而丙泊酚和瑞芬太尼的使用率更低。瑞芬太尼对 LVEF 降低的患者的影响与 LVEF 正常的患者不同(交互项 OR 2.71,95%CI 1.30-5.68,p=0.008)。虽然瑞芬太尼在具有正常收缩功能的患者中与较少的并发症相关(OR 0.54,95%CI 0.42-0.68,p<0.001),但在 LVEF 降低的患者中与并发症增加相关(OR=3.13,95%CI 3.06-5.98,p=0.026)。
在接受非心脏手术的患者中,与 LVEF 正常的患者相比,术前 LVEF 降低的患者的治疗方式不同。发现瑞芬太尼的使用与术后不良事件的增加之间存在关联,而这种关联仅在该人群中存在。需要进一步的研究来确定这种关系是继发于药物本身还是反映了瑞芬太尼在 LVEF 降低的患者中使用方式的差异。